These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35373352)

  • 21. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
    Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCMA in Multiple Myeloma-A Promising Key to Therapy.
    Kleber M; Ntanasis-Stathopoulos I; Terpos E
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Options at the time of relapse after anti-BCMA therapy.
    Razzo B; Garfall AL; Cohen AD
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):450-458. PubMed ID: 38066864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 25. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current use of bispecific antibodies to treat multiple myeloma.
    Lee H; Neri P; Bahlis NJ
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):332-339. PubMed ID: 38066842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teclistamab-cqyv in multiple myeloma.
    Martino EA; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
    Eur J Haematol; 2024 Mar; 112(3):320-327. PubMed ID: 37848191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific T-cell engagers for treatment of multiple myeloma.
    Ravi G; Costa LJ
    Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma.
    Rinaldi I; Muthalib A; Edina BC; Wiyono L; Winston K
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR T-Cells in Multiple Myeloma Are Ready for Prime Time.
    Rodríguez-Otero P; Prósper F; Alfonso A; Paiva B; San Miguel JF
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33172026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
    Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
    Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloma: next generation immunotherapy.
    Cohen AD
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):266-272. PubMed ID: 31808859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.
    Quazi S
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
    Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
    Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
    Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
    Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.